Background-Our aim was to assess the mortality and vascular morbidity risk of elderly individuals with asymptomatic versus symptomatic peripheral artery disease (PAD) in the primary care setting. Methods and Results-This prospective cohort study included 6880 representative unselected patients Ն65 years of age with monitored follow-up over 5 years. According to physician diagnosis, 5392 patients had no PAD, 836 had asymptomatic PAD (ankle brachial index Ͻ0.9 without symptoms), and 593 had symptomatic PAD (lower-extremity peripheral revascularization, amputation as a result of PAD, or intermittent claudication symptoms regardless of ankle brachial index). The risk of symptomatic compared with asymptomatic PAD patients was significantly increased for the composite of all-cause death or severe vascular event (myocardial infarction, coronary revascularization, stroke, carotid revascularization, or lower-extremity peripheral vascular events; hazard ratio, 1.48; 95% confidence interval, 1.21 to 1.80) but not for all-cause death alone (hazard ratio, 1.13; 95% confidence interval, 0.89 to 1.43), all-cause death/myocardial infarction/stroke (excluding lower-extremity peripheral vascular events and any revascularizations; hazard ratio, 1.18; 95% confidence interval, 0.92 to 1.52), cardiovascular events alone (hazard ratio, 1.20; 95% confidence interval, 0.89 to 1.60), or cerebrovascular events alone (hazard ratio, 1.33; 95% confidence interval, 0.80 to 2.20). Lower ankle brachial index categories were associated with increased risk. PAD was a strong factor for the prediction of the composite end point in an adjusted model. Conclusions-Asymptomatic PAD diagnosed through routine screening in the offices of primary care physicians carries a high mortality and/or vascular event risk. Notably, the risk of mortality was similar in symptomatic and asymptomatic patients with PAD and was significantly higher than in those without PAD. In the primary care setting, the diagnosis of PAD has important prognostic value.
A therosclerosis is a systemic disease that affects coronary, cerebral, and lower-extremity arteries and requires stringent secondary preventive measures to prevent premature mortality and morbidity. 1 The manifestation of atherosclerosis in the legs, peripheral artery disease (PAD), has long been underestimated and underdiagnosed in the primary care setting. 2, 3 A series of large-scale epidemiological studies have shown that the disease is widespread, particularly in the elderly and in patients with diabetes mellitus or clusters of cardiovascular risk factors. 4, 5 Furthermore, PAD was shown to be associated with increased risk for premature mortality and cardiovascular and cerebrovascular events. 6, 7 Only a few studies have been stratified for asymptomatic and symptomatic PAD cases, but they did not provide consistent outcomes. Criqui et al 8 described a progressive increase in patients with PAD who were asymptomatic, symptomatic, or severely symptomatic; Leng et al 9 demonstrated that asymptomatic PAD patients had higher event rates than symptomatic patients. In addition, McDermott et al 10 more recently reported that patients with asymptomatic PAD had poorer functional performance and quality of life than patients with intermittent claudication (IC). Overall, current data from the primary care setting on the prevalence and risk of premature mortality and of cardiovascular events associated with PAD are limited.
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Against this background, our objectives were to describe the prevalence of asymptomatic and symptomatic PAD in unselected elderly patients in a representative primary care setting in Germany, to investigate the long-term risk for total mortality or major vascular events in patients with PAD by clinical status (asymptomatic versus symptomatic) compared with individuals without PAD, and to quantify the association of PAD with outcomes compared with conventional cardiovascular risk factors.
Methods
The German Epidemiological Trial on Ankle Brachial Index (getABI) is an ongoing prospective observational cohort study initiated in October 2001. The methods and design of the study have been described elsewhere in greater detail. 11, 12 Briefly, 34 vascular physicians throughout Germany trained and supervised 344 general physicians (GPs) in their vicinity who were representative in terms of location (ZIP codes) and training (internists and general physicians) of the primary care setting in Germany. A prevalence assessment of primary care attendees, regardless of their reason for seeing the doctor, was then conducted in a prespecified week in October 2001. An average of 20 eligible patients per practice who fulfilled the inclusion criteria (age Ն65 years, legally competent, and able to cooperate appropriately and to provide written informed consent) were recruited evenly over this week to avoid selection bias. The only exclusion criterion was life expectancy Յ6 months as judged by the GP.
Medical History and Definitions at Baseline
A short physical examination was performed at baseline. Medical history assessment included the following conditions: cardiovascular events (myocardial infarction or coronary revascularization procedures); cerebrovascular events (stroke or revascularization procedures on the carotid arteries); lower-extremity peripheral vascular events (ie, a history of amputation [minor and major form] of the lower extremities because of PAD or revascularization procedures on the lower-extremity peripheral arteries); IC (ie, pain in the calf muscles while walking or during other exertion and disappearing within 10 minutes at rest); and risk factors such as arterial hypertension, diabetes mellitus, lipid disorders, or smoking. Subjects were defined as having diabetes mellitus if they had been assigned the clinical diagnosis by their physician, if their hemoglobin A 1c was Ն6.5% (criterion used in 94 cases), and/or if they were receiving any oral antidiabetic drug and/or insulin at baseline. Subjects were defined as having hypertension if they had been assigned the clinical diagnosis by their physician and/or if they were receiving AT 1 receptor antagonists, angiotensin-converting enzyme inhibitors, and/or diuretics at baseline. Subjects were defined as having lipid disorders if they had been assigned the clinical diagnosis by their physician, if they were receiving statins and/or fibrates, if their total cholesterol was Ն200 mg/dL at baseline, and/or if their triglyceride level was Ն150 mg/dL at baseline. All laboratory examinations were performed centrally. A cigarette smoking history was taken from all study subjects (never, current, past).
ABI at Rest
GPs were specifically trained to perform ABI measurements under standardized conditions. A standardized Doppler ultrasonic device was used in all centers (8-MHz Kranzbühler, General Electric, Solingen, Germany). Blood pressure measurements and ABI calcu-lations were performed according to the recommendations of the American Heart Association. 13 The ABI for each leg equals the ratio of the higher of the 2 systolic pressures (tibial posterior and anterior artery) above the ankle to the average of the right and left brachial artery pressures, unless there was a discrepancy Ն10 mm Hg in blood pressure values between the 2 arms. In such a case, the higher reading was used for the ABI. Pressures in each leg were measured, and the ABIs were calculated separately for each leg. The lower of the 2 ABI values was used for analyses.
Asymptomatic PAD was defined as resting ABI Ͻ0.90 13 with an absence of prior lower-extremity peripheral vascular events or clinical symptoms indicative of IC. Symptomatic PAD was defined as IC, history of lower-extremity peripheral vascular revascularization, and/or limb amputation because of PAD regardless of ABI value. Total PAD was defined as either symptomatic or asymptomatic PAD. Fifty-nine patients with incompressible arteries (Mönckeberg sclerosis) as indicated by an ABI Ͼ1.5 were excluded, as in other studies, to avoid misclassification. 14, 15 Cases with missing ABI values (nϭ8) and no past peripheral events or IC were classified as patients without PAD.
Primary Study Outcomes and Identification of Cardiovascular Events During Follow-Up
Severe vascular events were defined as follows: cardiovascular, including myocardial infarction or coronary revascularization; cerebrovascular, including stroke or carotid revascularization; and lowerextremity peripheral vascular, including peripheral revascularization or amputation because of PAD during follow-up. Information on patients' deaths and vascular events was obtained from the participating GPs, who were asked after 6 months and 1, 3, and 5 years to complete a case record form detailing the event. If possible, deaths resulting from cardiovascular or cerebrovascular causes were further investigated by verifying data from hospital or GP records to ensure that the protocol criteria were fulfilled. Deaths, coronary events, and peripheral events were not adjudicated. However, all strokes were further verified and adjudicated by 2 experienced neurologists independently who were unaware of the PAD status of patients.
Statistical Analyses
Characteristics of subjects at baseline were illustrated descriptively for all 6821 patients and separately by PAD categories. In addition, the differences between symptomatic and asymptomatic PAD patients at baseline were investigated exploratively with 2 tests and t tests. To assess associations between PAD, respective ABI categories (and conventional risk factors) and 5-year mortality/vascular morbidity incidence rates were calculated and Cox regression analyses were performed.
Incidence rates and their 95% confidence intervals (CIs) were calculated as events per 1000 person-years. Only the first event and time until first event were taken into account. The constant rate assumption was not met for the risks of interest. Therefore, the reported incidence rates have to be interpreted as a kind of average over the 5 years of the study.
Several unadjusted and adjusted Cox regression analyses were performed, and the corresponding hazard ratios (HRs) and their 95% CIs were calculated. When comparing PAD groups, we used 4 separate models: PAD no/unknown to PAD total (analysis includes all patients), PAD no/unknown to PAD asymptomatic (patients with symptomatic PAD were excluded), PAD no/unknown to PAD symptomatic (patients with asymptomatic PAD were excluded), and PAD asymptomatic to PAD symptomatic (patients without [or unknown] PAD were excluded).
To best illustrate the possible linear relations between low ABI values and the risk of death or vascular events, the ABI was categorized according to the cutoff points of 1.1, 0.9, 0.7, and 0.5 (the last category also includes history of peripheral revascularization or amputation resulting from PAD at baseline). When comparing ABI categories, we also used 4 separate models, with patients with an ABI Ն1.1 and Յ1.5 as the reference group in each case.
In addition to PAD groups, respectively ABI categories, the following variables were included in all adjusted statistical models: age (above/below median); gender; smoking status (never/ever); body mass index (Ն/Ͻ30 kg/m 2 ); history of severe cardiovascular or cerebrovascular events (yes/no or unknown); presence of diabetes mellitus, hypertension, and lipid disorders (each yes/no or unknown); and homocysteine (below/above the 4th quintile [19.1 mol/L]). These results were also used to compare the relative prognostic importance of PAD and the other conventional risk factors.
Further, to visualize the findings, time-to-event distributions in the categories were summarized with Kaplan-Meier curves.
Statistical significance was accepted at the 2-sided 0.05 level, and all CIs were computed at the 95% level. Statistical analyses were performed with SAS version 9.1 (SAS Institute Inc, Cary, NC).
Results

Characteristics of Subjects at Baseline
Of the 6880 patients included in this study, all but 59 (ABI Ͼ1.5, defined as patients with mediasclerosis) were analyzed. The survival status of all but 4 patients was known at the 5-year follow-up. According to physician diagnosis, 5392 patients had no PAD (79.0%), 836 had asymptomatic PAD (12.3%), and 593 had symptomatic PAD (8.7%; about one quarter had undergone peripheral artery revascularization or amputation). The Table displays the patient characteristics in the individual groups. Although there were no significant differences in age and most risk factors, in symptomatic PAD patients, the proportions of men, smokers, and patients with a history of cardiovascular or cerebrovascular events were higher. For mean body mass index, the opposite was true. Of note, the mean ABI was higher in symptomatic compared with asymptomatic PAD patients (0.85Ϯ0.23 versus 0.79Ϯ0.11). Figure 1 provides an overview of mortality events in total and by cause. Of patients without PAD, with asymptomatic PAD, and with symptomatic PAD, 19.5, 41.7, and 53.0 patients per 1000 patient-years had died. Compared with patients without PAD, those with asymptomatic PAD (HR, 1.66; 95% CI, 1.38 to 2.00) or symptomatic PAD (HR, 1.89; 95% CI, 1.55 to 2.30) had a significantly increased risk of premature death. No significant differences between asymptomatic and symptomatic PAD groups were found for death regardless of reason (cardiovascular, cerebrovascular, other, unknown reason). BMI indicates body mass index. Values are meanϮSD when appropriate. Patients with an ABI Ͼ1.5 were excluded. ABI was measured at baseline. PAD: ABI Ͻ0.9, history of IC, peripheral revascularization, or amputation because of PAD at baseline. Symptomatic PAD: IC, peripheral revascularization, and/or amputation resulting from PAD at baseline. Asymptomatic PAD: ABI Ͻ0.9 and no symptomatic PAD at baseline. For definition of diabetes mellitus, arterial hypertension, lipid disorders, etc, see the Methods section.
Mortality
*Comparison between symptomatic PAD and asymptomatic PAD groups (with t or x 2 test). †Patients with peripheral revascularization or amputation because of PAD at baseline were excluded (431 patients left in symptomatic group).
Composite Outcomes of All-Cause Mortality and Vascular Events
The composite end point of all-cause mortality or severe vascular events occurred in 27.2 (no PAD), 60.4 (asymptomatic PAD), and 104.7 (symptomatic PAD) cases per 1000 patient-years (Figure 2 , top). Compared with patients without PAD, those with asymptomatic PAD (HR, 1.81; 95% CI, 1.53 to 2.14) or symptomatic PAD (HR, 2.66; 95% CI, 2.25 to 3.15) had a significantly increased risk to experience the composite outcome, and the difference between the 2 PAD groups was significant (HR. 1.48; 95% CI, 1.21 to 1.80). Times to event for the composite outcomes by PAD status are also illustrated with Kaplan-Meier curves (Figure 3) .
The breakdown for the various vascular event types is displayed by PAD status in Tables Ia through If of the online-only Data Supplement. Between symptomatic and asymptomatic PAD, no significant differences were found for myocardial infarction, stroke, peripheral amputation resulting from PAD, and carotid revascularization, whereas rates in the symptomatic PAD group were significantly increased for coronary revascularization and peripheral revascularization. Figure 2 summarizes these findings and shows the patientyears and event rates for various individual and combined outcomes (all-cause death and/or severe vascular events) in the total PAD group and stratified for asymptomatic and symptomatic PAD, as well as the resulting adjusted risk increase compared with the group of patients without PAD.
The relative number of events and the corresponding risk increase were consistently higher in symptomatic PAD patients.
Of note, the number of cerebrovascular events, including ischemic/hemorrhagic stroke, was substantially lower than the number of cardiovascular events. The adjusted HR for cerebrovascular events in the total PAD group was slightly lower than the risk for cardiovascular events (HR, 1.45; 95% CI, 1.06 to 1.98; versus HR, 1.89; 95% CI, 1.56 to 2.28).
Impact of Peripheral Events
The difference between total events in the symptomatic PAD group and the asymptomatic PAD group appeared to be driven by a greater number of peripheral revascularizations performed in the symptomatic group; perhaps these events were triggered by symptoms. Two separate analyses with group comparisons were performed to investigate this finding (Figure 2 , middle, and Tables IIa and IIb of the online-only Data Supplement). In the first analysis, lower-extremity peripheral events (lower-extremity peripheral revascularization and amputation resulting from PAD) were excluded from the end point; in the second analysis, lower-extremity peripheral events and all revascularizations (coronary/carotid) were excluded from the end point ( Figure 2 ). In the first analysis, the relative risk of symptomatic PAD patients compared with asymptomatic PAD patients was lower than in the overall end point of all-cause death or severe vascular event (1.32; 95% CI, 1.05 to 1.64; versus 1.48; 95% CI, 1.21 to 1.80), but the difference between symptomatic PAD patients and asymptomatic PAD patients was still significant. In the second analysis, the relative risk of PAD patients compared with non-PAD patients was similar (1.85; 95% CI, 1.57 to 2.17), but the difference between symptomatic PAD patients and asymptomatic PAD patients did not remain significant (1.18; 95% CI, 0.92 to 1.52).
ABI Category
In the analysis by ABI category, patients with an ABI of 1.1 to 1.5 had the lowest event rate per 1000 patient-years (24.3 events), whereas event rates increased substantially with decreasing ABI. In patients with an ABI Ͻ0.5, lowerextremity peripheral revascularization, or amputation resulting from PAD, event rates were increased 6-fold (146.3), and the corresponding adjusted risk was increased 4.65-fold (95% CI, 3.57 to 6.05). This finding is illustrated with event-free survival by ABI category in Figure 4 , and further details are provided in the 
Intermittent Claudication
In a supplementary analysis, ABI was included as a continuous variable in the adjusted statistical model, along with the other risk factors. Patients with IC had lower ABI values than patients without IC, particularly among patients with an ABI Ͻ0.9 (Table IVa of the online-only Data Supplement). There was a significant independent prognostic effect of IC for death resulting from any cause in an adjusted model including ABI groups (Ͻ0.9/Ն0.9); however, in the model with continuous ABI values, it was lower and did not remain signif- Figure 2 . Adjusted risk (hazard rations, 95% CIs) of death and/or severe vascular events in patients with PAD compared to individuals without PAD. HRs as a result of a Cox regression analysis adjusted for diabetes mellitus, hypertension, lipid disorders, age (above median), sex, body mass index (Ն30 kg/m 2 ), smoking (ever), history of severe cardiovascular or cerebrovascular events, and homocysteine (Ͼ4th quintile, 19.1 mol/L) at baseline. ABI was measured at baseline. PAD if not specified otherwise includes asymptomatic and symptomatic cases: ABI Ͻ0.9, history of IC, peripheral revascularization, or amputation because of PAD at baseline. For definition of diabetes mellitus, arterial hypertension, lipid disorders, etc, see the Methods section. Patients with an ABI Ͼ1.5 were excluded. Patients with events in 2 or 3 categories are mentioned in the respective categories. a nϭ5,392; b nϭ1,429; c nϭ836; d nϭ593; e Severe vascular events: myocardial infarction, coronary revascularization, stroke, carotid revascularization, lowerextremity peripheral revascularization, or amputation. f Severe cardiovascular events (myocardial infarction or coronary revascularization) or severe cerebrovascular events (stroke or carotid revascularization). g Fatal or nonfatal stroke or carotid revascularization. h Myocardial infarction, coronary revascularization, or death resulting from a cardiovascular event. i Lower-extremity peripheral revascularization or amputation.
icant (Table IVb of the online-only Data Supplement). The prognostic effect of IC for death resulting from any cause or severe vascular event was greater than that for death resulting from any cause alone and was significant in both models ( Table IVc of 
Independent Association of PAD With Outcomes
After adjustment for known conventional risk factors in the adjusted model, PAD had the strongest independent association with death or severe vascular events (HR, 2.17; 95% CI, 1.90 to 2.48). Male gender, previous cardiovascular or cerebrovascular events, diabetes mellitus, high age, smoking, and high homocysteine levels were also significant factors in this model ( Figure 5 ).
Discussion
The present large-scale prospective study shows that 1 in 5 elderly patients visiting their primary care physician has PAD (12.2% asymptomatic, 8.7% symptomatic). With few exceptions, previous epidemiological studies have not differentiated between asymptomatic and symptomatic PAD but have focused on an ABI threshold (usually Ͻ0.9) for the diagnosis of PAD. 16 -20 In our study, regardless of the event type (death and/or severe vascular events), patients with PAD had a significantly increased risk compared with those without PAD. Within the PAD group, the risk of symptomatic PAD compared with asymptomatic PAD patients was significantly increased by Ϸ50% (HR, 1.48) for the composite end point of all-cause death or severe vascular event but not significantly for all-cause mortality alone (HR, 1.13), death/myocardial infarction/stroke (ie, excluding any peripheral events and any revascularizations; HR, 1.18), or cardiovascular or cerebrovascular events when assessed separately. Thus, asymptomatic PAD diagnosed through routine screening in the offices of primary care physicians carries a high 5-year mortality and cardiovascular or cerebrovascular event risk that is not substantially lower than that of symptomatic PAD. This early form of PAD has previously been underestimated, underdiagnosed, and undertreated because of a mistaken belief that it is relatively benign. 2, 3 The high mortality and vascular event rates, however, show the high risk that these patients face and the importance of treating the condition early.
The majority of earlier observational studies that investigated the risk of PAD patients were population based 8, [21] [22] [23] or done in high-risk patients. 24 Cohorts in the primary care setting 20, 25 (particularly if source data are verified by monitoring as in our study) compared with population-based studies are likely to be characterized more thoroughly in terms of comorbidities and outcomes, and their results are more likely to be directly applicable to routine care. Generally, the risk increase associated with PAD observed in our study is on the same order as in previous population-based studies that used ABI cutoffs of 0.9 (in some studies, 0.85 or 0.5), as systematically reviewed by Doobay and Anand. 6 They found, compared with individuals without PAD, a mean unadjusted relative risk of 3.2 (95% CI, 2.6 to 3.9) and adjusted risks between 1.6 and 3.1, depending on the individual study, for all-cause mortality. Moreover, they found an unadjusted relative risk of 2.3 (95% CI, 1.5 to 3.7) and adjusted risk between 1.4 and 2.7 for cardiovascular events.
Because rates for cerebrovascular events are substantially lower than those for cardiovascular events, large cohorts and/or long follow-up periods are necessary to address the question of whether the respective risk is increased in PAD patients. Thus, compared with coronary morbidity and mortality, cerebrovascular events have been infrequently reported with inconclusive results. The Edinburgh Artery Study 25 and the Atherosclerosis Risk in Communities Study 26 found a significant risk increase for stroke, whereas the Cardiovascular Health Study (after multivariable adjustment) did not. 23 In our study, in the total PAD cohort, the adjusted HR of cerebrovascular events, if not differentiated between type of stroke, was significantly increased (HR, 1.5). Notably, in the group of asymptomatic PAD patients, the risk increase was not significant, which may be due to small power owing to low event numbers.
An important finding of the present study is that PAD (asymptomatic and symptomatic), after adjustment for multiple known cardiovascular risk factors, had a significant association with the composite outcome of death or vascular events. The association between PAD and the composite outcome was considerably stronger than with conventional risk factors, including diabetes mellitus or smoking. This result is in line with the majority of the older investigations focusing on low ABI, 6 showing that PAD provides additional information on risk beyond the assessment of conventional risk factors. Hypertension and lipid disorders had no significant effect in the model, which may be due to pretreatment or the advanced age of the cohort. 27 Table. Severe vascular events: myocardial infarction, coronary revascularization, stroke, carotid revascularization, lower-extremity peripheral revascularization, or amputation. ABI was measured at baseline. PAD includes asymptomatic and symptomatic cases: ABI Ͻ0.9, history of IC, lower-extremity peripheral revascularization, or amputation because of PAD at baseline. For definition of diabetes mellitus, arterial hypertension, and lipid disorders, see the Methods section. Patients with an ABI Ͼ1.5 were excluded.
Certain types of vascular events are prompted by symptoms, namely revascularizations and amputations in the lower extremities (which are usually performed in patients with claudication), as well as most revascularizations of the carotid and coronary arteries. So, it could be expected that after the exclusion of all events that are influenced by symptoms and consequently physician decision, the risk difference between symptomatic and asymptomatic PAD decreases. Indeed, the difference between asymptomatic and symptomatic PAD patients was reduced somewhat after the exclusion of all lower-extremity peripheral vascular events from the analyses (HR, from 1.48 to 1.32) and to a greater extent after additional exclusion of revascularizations of the carotid and coronary arteries (HR, 1.18, no longer significant).
In our study, the ABI was measured by GPs or their staff. A recent validation study involving getABI investigators showed that between vascular experts, GPs, and nurses, no significant differences exist with respect to measurement variance. 28 Therefore, the ABI measurement can be performed with reliable results after minimal training. It must be noted, however, that the intraobserver and interobserver variability of this investigation is 8% to 9%, which calls for confirmation measurements in patients near the 0.9 threshold to categorize them correctly. 28 Furthermore, as shown in our analysis, the ABI value not only is of high interest for the PAD diagnosis but also conveys relevant information on the individual patient's risk.
Conclusions
The prevalence of PAD in the primary care setting is alarmingly high, which supports the routine use of ABI measurements to identify patients who are at high risk for premature death and vascular events. Measurement of ABI at baseline provides prognostic information that cannot be derived from conventional risk factors alone. Patients with asymptomatic PAD have a significantly increased risk compared with patients without PAD, which calls for risk reduction measures such as stringent lipid-lowering and antiplatelet treatment. In terms of treatment (ie, secondary prevention), the current American Heart Association/American College of Cardiology guidelines or Transatlantic Inter-Society Consensus II guidelines do not differentiate between asymptomatic and symptomatic PAD patients, 4,5 and our results corroborate this approach. The present study confirms the importance of PAD as an indicator disease for generalized atherosclerosis, and its high prognostic utility, in primary care. 
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